The Australian government has made numerous claims for damages against patentees for savings forgone when an interlocutory/preliminary injunction (PI) delays generic launch but...
A hard lesson learnt: Commonwealth v Sanofi
read more
BioBlast w/e 27 Oct 23
27 OCT 2023 | US | Sanofi to Spin-Off Consumer Business and Focus on Biopharma by End Q4 2023 Sanofi announced that it will separate its Consumer Healthcare Business as soon as...
Special Counsel Julie Ballance joins Pearce IP as it expands into New Zealand
Pearce IP is delighted to announce that leading intellectual property specialist Julie Ballance (Patent Attorney, Lawyer and Notary, NZ) commenced with Pearce IP as a Special...
BioBlast w/e 23 Oct 23
23 OCT 2023 | US | Approval Alert: FDA Approves Celltrion’s Zymfentra® (infliximab-dyyb), Biosimilar to Janssen’s Remicade®, and the First Approved SC Infliximab...
BioBlast w/e 15 Oct 23
15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on its SB16 (denosumab, biosimilar to Amgen’s Prolia®) at the...
Advanta succeeds again in second extension of time application opposed by Nufarm
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Breakthrough Mining Innovator Globaltech wins AU Patent Battle against Market Leader Reflex
An Australian Court has found in favour of Globaltech which solved a mining problem with an elegant solution. An important lesson from this decision is that driving IP innovation can be central to maintaining a market-leading position.
BioBlast w/e 07 Oct 23
07 OCT 2023 | Samsung Bioepis Presents Switching Study Results for SB15, Biosimilar to Regeneron’s Eylea® (aflibercept) Samsung Bioepis announced its Phase III switching study...
When perceiving the problem is the inventive step – complacent market leader Reflex infringes disruptor Globaltech’s valid patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 02 Oct 23
02 OCT 2023 | Nobel Prize Awarded to Katalin Karikó and Drew Weissman for Their Work Which Supported the mRNA COVID-19 Vaccine The Nobel Assembly at Karolinska...
Zoetis Vaccine Patent Survives Opposition Appeal by the Hair of its Chinny Chin Chin
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 22 Sep 23
22 SEP 2023 | KR | Prestige Biologics Partners with Dr. Reddy’s Laboratories Subsidiary in Strategic Manufacturing Collaboration Prestige Biologics, a contract development and...
BioBlast w/e 15 Sep 23
15 SEP 2023 | US | Novartis Shareholders Approve Sandoz Spin-Off On 15 September 2023, Novartis shareholders approved the proposed Sandoz spin-off, Novartis’ generics and...
Federal Court Shines Light on Patent Litigation Case Management
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 08 Sep 23
08 SEP 2023 | Coherus Completes Acquisition Of Surface Oncology Coherus Biosciences announced that it completed its acquisition of Surface Oncology, Inc., a clinical-stage...
No Anshun Estoppel in Fourth VMS Validity Challenge
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 01 Sep 23
01 SEP 2023 | AU | Celltrion Submits Marketing Application For CT-P43, Biosimilar To Janssen’s Stelara® (Ustekinumab) Business Korea reported that Celltrion filed an application...
BioBlast w/e 25 Aug 23
25 AUG 2023 | US | Celltrion and J&J Reach Patent Settlement Regarding Ustekinumab Korea Biomedical Review reported that Celltrion has finalised an agreement with Johnson...
BioBlast w/e 18 Aug 23
18 AUG 2023 | US | FDA Approves Regeneron’s 8mg Eylea® (Aflibercept) For wAMD, DME and DR Regeneron announced that the FDA approved its 8mg Eylea® (aflibercept) to treat Wet...
BioBlast w/e 12 Aug 23
12 AUG 2023 | US | Biocon Confirms Viatris North American Transition Will Complete By End Q3 2023 According to the Business Standard Biocon Biologics’ CEO has confirmed the...
Car Park App Scrap Reaches the Merits Stage
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Pearce IP dominates 2023 WIPR Leaders lists for Patents and Trade Marks
We are pleased to announce that 3 Pearce IP leaders are ranked amongst the world’s best patent and trade mark practitioners by WIPR Leaders 2023. Pearce IP’s Executives Naomi...
BioBlast w/e 04 Aug 23
03 AUG 2023 | US | Teva confirms intention to launch US adalimumab biosimilar AVT02 in 2024 Teva’s CEO confirmed that it will still pursue launching its Alvotech...
BioBlast w/e 28 Jul 23
27 JUL 2023 | EU | New indication alert: AZ’s Soliris® (eculizumab) approved to treat gMG in children aged six to 17 AstraZeneca announced that the EMA has approved Soliris®...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.